Sale of Bertin Pharma’s pharmaceutical development activities

Sector(s)
Healthcare
Deal type
Carve out / Sell your business
Date
August 2017
Countries involved
France

Client

CNIM is a French industrial engineering contractor and equipment manufacturer that operates in the sector of Environment, Energy, Defense and High Technologies

Deal

Capitalmind advised CNIM Group on the sale of Bertin Pharma’s pharmaceutical development activities to Amatsigroup (Eurofins)

Parties

Lead team

  • Michel Degryck

    Michel Degryck

    Managing Partner France
  • Kilian de Gourcuff

    Kilian de Gourcuff

    Partner France

What we did

Capitalmind supported the CNIM Group throughout the entire sale process: preparation of marketing documentation, research and selection of strategic buyers and management of carve-out issues.

About the deal

Amatsi Group acquired the pharmaceutical development activities of Bertin Pharma.
Amatsi Group, a subsidiary of the Eurofins Group, is a pharmaceutical development company with a portfolio of 300+ international customers which includes players from both the pharmaceutical and biotechnology businesses. In 2016, the company generated revenues of 45 million euros and had more than 350 highly qualified employees in life sciences.

Subscribe to our news & insights




Sector preference